Seeing Is Believing
Currently out of the existing stock ratings of Matt O'brien, 612 are a BUY (84.53%), 107 are a HOLD (14.78%), 5 are a SELL (0.69%).
Analyst Matt O'brien, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 64.47% that have a potential upside of 27.7% achieved within 167 days.
Matt O'brien’s has documented 1,583 price targets and ratings displayed on 54 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on PEN, Penumbra at 20-Nov-2024.
Analyst best performing recommendations are on RMED (RA MEDICAL SYSTEMS).
The best stock recommendation documented was for KRMD (REPRO MED SYSTEMS) at 1/25/2021. The price target of $4.5 was fulfilled within 1 day with a profit of $0.63 (12.28%) receiving and performance score of 122.81.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$388
$6.98 (1.83%)
$355
2 years 1 months 15 days ago
(02-Nov-2022)
2/5 (40%)
$14.49 (3.88%)
88
Hold
$380
$-1.02 (-0.27%)
$235
2 years 1 months 15 days ago
(02-Nov-2022)
1/2 (50%)
$6.49 (1.74%)
36
Hold
$380
$-1.02 (-0.27%)
$350
2 years 1 months 16 days ago
(01-Nov-2022)
24/41 (58.54%)
$2.18 (0.58%)
138
Buy
$300
$-81.02 (-21.26%)
$425
2 years 2 months 5 days ago
(12-Oct-2022)
1/2 (50%)
$57.23 (23.57%)
20
Sell
$235
$-146.02 (-38.32%)
$275
2 years 5 months 2 days ago
(15-Jul-2022)
6/8 (75%)
$-33.23 (-12.39%)
142
Which stock is Matt O'brien is most bullish on?
Which stock is Matt O'brien is most reserved on?
What Year was the first public recommendation made by Matt O'brien?